FRANKLIN LAKES, N.J. (Oct. 1, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced Bridget Bagnato has been named president of BD Specimen Management, effective today.  

Bagnato will be responsible for driving global strategic, operational, commercial performance and customer experience across the Specimen Management portfolio and will report to Dave Hickey, executive vice president (EVP) and president of the Life Sciences Segment. Bagnato joined BD Integrated Diagnostic Solutions in July as vice president and general manager (VP/GM) of Specimen Management from the BD Surgery business.

“Bridget has been with BD for nearly 25 years working across all three segments ― Medical, Interventional and Life Sciences ― and brings broad and robust BD experience to the role,” said Hickey. “She has a proven ability to lead with a growth mindset and will continue to bring her commitment and strategic acumen to the Specimen Management team. This move is another example of our commitment to leveraging experience and learnings across the enterprise.”

During her career at BD, Bagnato has had a variety of roles, including VP/GM for the Injection business in Diabetes Care, and senior business director for the Vascular Care platform in Medication Delivery Solutions. Bagnato holds a bachelor’s degree from Villanova University and an MBA from The Fuqua School of Business at Duke University.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:

Media:                                                                                                                  Investors:

Troy Kirkpatrick                                                                                                 Adam Reiffe
VP, Public Relations                                                                                         Senior Director, Investor Relations
858.617.2361                                                                                                      201.847.6927
troy.kirkpatrick@bd.com                                                                              adam.reiffe@bd.com